FierceBiotech Names Achaogen as One of the “Fierce 15" Biotech Companies of 2009

- Achaogen is on Leading Edge of Biotech -

San Francisco, CA, June 30, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today that it has been selected as one of the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotech companies of 2009. The editors of FierceBiotech evaluated hundreds of privately-held firms based on vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position.

An internationally recognized daily newsletter reaching more than 65,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day’s top stories, with a special focus on drug discovery and clinical trials.

“New insights have helped Achaogen create a new and differentiated antibiotic – and that’s important in a field that is dominated by therapies fated to become obsolescent. An innovative blend of venture capital and non-dilutive financing sources has helped bankroll this five-year-old biotech, which is firmly focused on improved efficacy with fewer side effects. Achaogen has good science and a sound business model, which is rarely paired in any industry,” said John Carroll, Editor of FierceBiotech.

"FierceBiotech is highly valued for its advanced understanding of biotechnology companies and the industry as a whole," said Kevin Judice, Ph.D., Chief Executive Officer and Chief Scientific Officer of Achaogen. "Being selected as a member of the ‘Fierce 15’ is an honor that recognizes Achaogen’s potential to make a significant impact in the biotech and antibacterial market.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. The complete list of ‘Fierce 15’ companies is available in today’s issue of FierceBiotech and on the FierceBiotech Web site at

About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science, developing drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis.

South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the U.S. Department of Defense, the Wellcome Trust and other sources. Venture capital investors include 5AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at

About FierceMarkets
FierceMarkets is a digital business media serving vertical markets with email newsletters, web sites, and live events. Based in Washington, DC, FierceMarkets publications reach more than 450,000 executives in over 100 countries every business day. Current publications include The Business VoIP Report (, FierceBioResearcher (, FierceBiotech (, FierceBroadbandWireless (, FierceCIO (, Fierce CIO: Tech Watch (, FierceDeveloper (, FierceFinance (, FierceFinanceIT (, FierceHealthCare (, FierceHealthFinance (, FierceHealthIT (, FierceIPTV (, FierceMobileContent (, FierceMobileIT (, FierceOnlineVideo (, FiercePharma (, FierceSarbox (, FierceTelecom (, FierceVaccines (, FierceVoIP (, FierceWireless (, and FierceWireless: Europe (

Ashlea Kosikowski, Pure Communications
(910) 547-7093

Heather Cox, FierceMarkets, Inc.
(202) 628-8778 x13